Adamis Pharma Stock Jumps After Naloxone Injection Under FDA Review For Opioid Overdose


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


  • The FDA has accepted for review Adamis Pharmaceuticals Corporation's (NASDAQ:ADMP) marketing application seeking approval for Zimhi, a naloxone injection for opioid overdose.
  • The agency's target action date is November 12.
  • The company resubmitted the application in May after it received a complete response letter in November 2020.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: ADMP shares are up 11.9% at $1.13 during the premarket session on the last check Wednesday.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralBriefsOpioids